Endocannabinoid metabolism and uptake: novel targets for neuropathic and inflammatory pain
10.1038/sj.bjp.0707433
Crossref journal-article
Wiley
British Journal of Pharmacology (311)
Abstract

Cannabinoid CB1and CB2receptors are located at key sites involved in the relaying and processing of noxious inputs. Both CB1and CB2receptor agonists have analgesic effects in a range of models of inflammatory and neuropathic pain. Importantly, clinical trials of cannabis‐based medicines indicate that the pre‐clinical effects of cannabinoid agonists may translate into therapeutic potential in humans. One of the areas of concern with this pharmacological approach is that CB1receptors have a widespread distribution in the brain and that global activation of CB1receptors is associated with adverse side effects. Studies of the endogenous cannabinoids (endocannabinoids) have demonstrated that they are present in most tissues and that in some pain states, such as neuropathic pain, levels of endocannabinoids are elevated at key sites involved in pain processing. An alternative approach that can be used to harness the potential therapeutic effects of cannabinoids is to maximise the effects of the endocannabinoids, the actions of which are terminated by re‐uptake and metabolism by various enzymes, including fatty acid amide hydrolase (FAAH), monoacylglycerol lipase (MAGL) and cyclooxygenase type 2 (COX2). Preventing the metabolism, or uptake, of endocannabinoids elevates levels of these lipid compounds in tissue and produces behavioural analgesia in models of acute pain. Herein we review recent studies of the effects of inhibition of metabolism of endocannabinoids versus uptake of endocannabinoids on nociceptive processing in models of inflammatory and neuropathic pain.British Journal of Pharmacology(2007)152, 624–632; doi:10.1038/sj.bjp.0707433; published online 20 August 2007

Bibliography

Jhaveri, M. D., Richardson, D., & Chapman, V. (2007). Endocannabinoid metabolism and uptake: novel targets for neuropathic and inflammatory pain. British Journal of Pharmacology, 152(5), 624–632. Portico.

Authors 3
  1. M D Jhaveri (first)
  2. D Richardson (additional)
  3. V Chapman (additional)
References 117 Referenced 116
  1. 10.1038/nn1916
  2. 10.1016/S0014-2999(00)00226-0
  3. 10.1124/jpet.104.075267
  4. 10.1042/bj3510817 / Biochem J / N‐Acyl‐dopamines: novel synthetic CB(1) cannabinoid‐receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo by Bisogno T (2000)
  5. 10.1042/bj3220671 / Biochem J / Biosynthesis, release and degradation of the novel endogenous cannabimimetic metabolite 2‐arachidonoylglycerol in mouse neuroblastoma cells by Bisogno T (1997)
  6. 10.1038/28393
  7. 10.1038/sj.bjp.0706699
  8. 10.1016/j.mvr.2005.02.001
  9. 10.1016/S0304-3959(01)00454-7
  10. 10.1038/sj.bjp.0704900
  11. 10.1038/sj.bjp.0706798
  12. 10.1073/pnas.161191698
  13. 10.1038/384083a0
  14. 10.1002/neu.20080
  15. 10.1073/pnas.0401292101
  16. 10.1096/fj.05-4943fje
  17. 10.1124/mol.59.6.1369
  18. 10.1016/S0014-2999(02)01996-9
  19. 10.1016/j.bcp.2005.05.011
  20. 10.1126/science.1470919
  21. 10.1073/pnas.152334899
  22. 10.1111/j.1460-9568.2004.03690.x
  23. 10.1016/j.pain.2005.09.005
  24. 10.1073/pnas.92.8.3376
  25. 10.1124/jpet.104.078980
  26. 10.1073/pnas.0400997101
  27. 10.1016/B0-443-07287-6/50012-6
  28. 10.1080/1475636021000049726
  29. 10.1016/S0006-2952(01)00712-2
  30. 10.1038/sj.bjp.0704937
  31. 10.1523/JNEUROSCI.5054-03.2004
  32. 10.1073/pnas.0730816100
  33. 10.1016/j.lfs.2005.05.007
  34. 10.1016/S0006-2952(98)00314-1
  35. 10.1016/S0014-5793(97)01603-7
  36. 10.1038/sj.bjp.0706990
  37. 10.1016/j.ejphar.2006.08.045
  38. 10.1208/aapsj080247
  39. 10.1016/j.neuropharm.2004.12.012
  40. 10.1074/jbc.M501489200
  41. 10.1208/aapsj080479
  42. 10.1038/nature03658
  43. 10.1038/sj.bjp.0706348
  44. 10.1038/sj.bjp.0704113
  45. 10.1073/pnas.122196999
  46. 10.1073/pnas.1834309100
  47. 10.1016/S0006-8993(97)01293-6
  48. 10.1046/j.1471-4159.2000.0742597.x
  49. 10.1038/sj.bjp.0706510
  50. 10.1523/JNEUROSCI.3326-06.2006
  51. 10.1016/j.pnpbp.2004.05.027
  52. 10.1038/nm803
  53. 10.1021/jm960152y
  54. 10.1074/jbc.M206788200
  55. 10.1074/jbc.M201084200
  56. 10.2174/1381612043453081
  57. 10.1021/bi034471k
  58. 10.1074/jbc.M104467200
  59. 10.1074/jbc.M007088200
  60. 10.1124/jpet.105.100792
  61. 10.1021/jm980461j
  62. 10.1016/S0014-2999(03)01430-4
  63. {'key': 'e_1_2_10_64_1', 'article-title': 'Immunohistochemical localisation of anandamide degrading enzyme: fatty acid amide hydrolase (FAAH) in rat dorsal root ganglion and spinal cord tissue', 'author': 'Lever IJ', 'year': '2006', 'journal-title': '16th Annual Symposium of International Cannabinoid Research Society'} / 16th Annual Symposium of International Cannabinoid Research Society / Immunohistochemical localisation of anandamide degrading enzyme: fatty acid amide hydrolase (FAAH) in rat dorsal root ganglion and spinal cord tissue by Lever IJ (2006)
  64. 10.1124/jpet.104.069401
  65. 10.1042/bj20031812
  66. 10.1021/jm0210818
  67. 10.1021/jm015545y
  68. 10.1016/S0014-5793(00)01223-0
  69. 10.1006/bbrc.2000.3869
  70. 10.1124/jpet.105.093286
  71. 10.1038/sj.bjp.0707145
  72. 10.1016/S0304-3959(01)00321-9
  73. 10.1016/j.ejphar.2006.09.072
  74. 10.1016/j.pharmthera.2004.07.008
  75. 10.1016/0006-2952(95)00109-D
  76. 10.1016/j.pain.2006.06.016
  77. 10.1021/bi002303b
  78. 10.1523/JNEUROSCI.4830-06.2007
  79. 10.1016/S0306-4522(03)00126-X
  80. 10.1016/S0306-4522(02)00870-9
  81. 10.1074/jbc.M413260200
  82. 10.1016/S0006-2952(03)00109-6
  83. 10.1021/bi049395f
  84. 10.1124/pr.58.3.2
  85. 10.1111/j.1460-9568.2006.05086.x
  86. 10.1016/j.phrs.2006.07.006
  87. 10.1016/S0301-0082(00)00031-9
  88. 10.1016/j.neuropharm.2006.08.011
  89. 10.1016/j.brainresrev.2006.02.002
  90. 10.1097/00000542-200310000-00031
  91. 10.1016/j.pbb.2006.03.011
  92. {'key': 'e_1_2_10_93_1', 'article-title': 'Effects of inhibition of FAAH on levels of endocannabinoids in the hindpaw and spinal cord of rats with a carrageenan‐induced inflamed hindpaw', 'author': 'Richardson D', 'year': '2007', 'journal-title': 'British Pharmacological Society and 3rd European Workshop on Cannabinoid Research PO33'} / British Pharmacological Society and 3rd European Workshop on Cannabinoid Research PO33 / Effects of inhibition of FAAH on levels of endocannabinoids in the hindpaw and spinal cord of rats with a carrageenan‐induced inflamed hindpaw by Richardson D (2007)
  93. {'key': 'e_1_2_10_94_1', 'article-title': 'Effects of fatty acid amide hydrolase and cyclooxygenase‐2 inhibitors on nociceptive behaviour in the carrageenan model of inflammatory pain in rats', 'author': 'Robinson I', 'year': '2006', 'journal-title': 'Proceedings of British Pharmacological Society Meeting Dec 2006'} / Proceedings of British Pharmacological Society Meeting Dec 2006 / Effects of fatty acid amide hydrolase and cyclooxygenase‐2 inhibitors on nociceptive behaviour in the carrageenan model of inflammatory pain in rats by Robinson I (2006)
  94. {'key': 'e_1_2_10_95_1', 'article-title': 'Effects of inhibition of cyclooxygenase 2 on levels of endocannabinoids in the carrageenan model of inflammatory pain', 'author': 'Robinson I', 'year': '2007', 'journal-title': 'British Pharmacological Society and 3rd European Workshop on Cannabinoid Research PO34'} / British Pharmacological Society and 3rd European Workshop on Cannabinoid Research PO34 / Effects of inhibition of cyclooxygenase 2 on levels of endocannabinoids in the carrageenan model of inflammatory pain by Robinson I (2007)
  95. 10.1016/j.ejphar.2004.12.031
  96. 10.1124/jpet.107.119941
  97. 10.1111/j.1460-9568.2005.04206.x
  98. 10.4049/jimmunol.170.10.4953
  99. 10.1113/jphysiol.2006.105569
  100. 10.1016/j.pain.2004.01.020
  101. 10.1016/j.jdermsci.2005.01.007
  102. 10.1006/bbrc.1995.2437
  103. 10.1146/annurev.pharmtox.42.092401.143905
  104. 10.1097/00115550-200507000-00007
  105. 10.1016/S0376-8716(96)01277-X
  106. 10.1016/S0090-6980(02)00053-9
  107. {'key': 'e_1_2_10_108_1', 'first-page': '27', 'article-title': 'A hydrolase enzyme inactivating endogenous ligands for cannabinoid receptors', 'volume': '45', 'author': 'Ueda N', 'year': '1998', 'journal-title': 'J Med Invest'} / J Med Invest / A hydrolase enzyme inactivating endogenous ligands for cannabinoid receptors by Ueda N (1998)
  108. 10.1016/j.neuropharm.2004.12.008
  109. 10.1038/sj.bjp.0706971
  110. 10.1016/S0163-7258(02)00252-8
  111. 10.1073/pnas.96.21.12198
  112. 10.1194/jlr.M300475-JLR200
  113. 10.1016/j.ejphar.2005.10.043
  114. 10.1111/j.1527-3466.2004.tb00134.x
  115. 10.1523/JNEUROSCI.21-16-05847.2001
  116. 10.1074/jbc.272.34.21181
  117. 10.1016/S0022-3565(24)37166-6 / J Pharmacol Exp Ther / Inhibition of cyclooxygenase‐2 rapidly reverses inflammatory hyperalgesia and prostaglandin E2 production by Zhang Y (1997)
Dates
Type When
Created 18 years ago (Aug. 20, 2007, 7:11 a.m.)
Deposited 7 months, 1 week ago (Jan. 20, 2025, 8:36 a.m.)
Indexed 5 days, 12 hours ago (Aug. 26, 2025, 2:31 a.m.)
Issued 17 years, 9 months ago (Nov. 1, 2007)
Published 17 years, 9 months ago (Nov. 1, 2007)
Published Online 16 years, 7 months ago (Jan. 29, 2009)
Published Print 17 years, 9 months ago (Nov. 1, 2007)
Funders 0

None

@article{Jhaveri_2007, title={Endocannabinoid metabolism and uptake: novel targets for neuropathic and inflammatory pain}, volume={152}, ISSN={1476-5381}, url={http://dx.doi.org/10.1038/sj.bjp.0707433}, DOI={10.1038/sj.bjp.0707433}, number={5}, journal={British Journal of Pharmacology}, publisher={Wiley}, author={Jhaveri, M D and Richardson, D and Chapman, V}, year={2007}, month=nov, pages={624–632} }